Ms. Shaw is a first-generation entrepreneur with over 44 years of experience in the field of biotechnology. She is a recipient of ‘Padma Shri’ and the ‘Padma Bhushan’ awards. She was also conferred with the highest French distinction – Chevalier de l’Ordre National de la Légion ’Honneur (Knight of the Legion of Honour) in 2016. She is ranked #1 in the Business Captains category in Global ‘Medicine Maker Power List’ 2018. Ms. Shaw is the only Indian in the Hurun Global Self-Made Women Billionaires List 2017. She is also the Chairperson and Managing Director of Biocon Limited, Independent Director on the Board of Infosys and United Breweries Ltd.

Jonathan holds a BA (Business Studies & Economics) degree from the University of Sheffield, United Kingdom and has done his MBA from Durham University, United Kingdom. He is responsible for leading Syngene’s business operations as well as steering its investments in developing and strengthening its capabilities and capacities. He has more than 25 years of extensive experience in the global biopharmaceuticals industry. Prior to joining Syngene in January 2015, he worked with Astrazeneca for over a decade where he has held various leadership positions including President & Director of Astrazeneca, Austria and President & COO, Astrazeneca India.

Professor Rosenberg received her Diplomed’Ingénieur’ from the Ecole Nationale Superieure des Telecommunications de Bretagne and an M.S. (Computer Science)from the University of California. She also earned a ‘Doctorat en Sciences’ from the Universite de Paris XI. She is a Fellow Member of the Institute of Electrical and Electronics Engineers and was elected a Fellow Member of the Canadian Academy of Engineering in 2013. At present, Prof. Rosenberg is the Canada Research Chair in the Future Internet, the Cisco Research Chair in 5G Systems and a professor in electrical and computer engineering at the University of Waterloo, Canada. At Syngene, Professor Catherine Rosenburg is a member of Nomination and Remuneration Committee, Corporate Social Responsibility Committee and Risk Management Committee.

Mr. Blackburn is a graduate in Management Sciences from Warwick University, United Kingdom, and has a professional accounting qualification from Institute of Cost and Management Accountants, United Kingdom. With more than 40 years experience in the field of finance, he worked as senior finance executive at GlaxoSmithKline, UK. Currently, he is also on the Board of Mereo Biopharma Group Plc. At Syngene, Paul Blackburn is a Chairman of Audit Committee and Risk Management Committee, and a member of Stakeholders Relationship Committee.

Dr. Kuchroo has a doctorate in Pathology from the University of Queensland, Australia. He is also the Samuel L. Wasserstrom Professor of Neurology at the Harvard Medical School, United States, and has 25 patents and over 325 research papers in immunology. He is a Member of the Scientific Advisory Boards of leading pharmaceutical companies including Pfizer, Novartis and GSK. He founded five different biotech companies including CoStim Pharmaceuticals and Tempero Pharmaceuticals. At Syngene, Dr. Vijay Kuchroo is a member of Nomination and Remuneration Committee, Corporate Social Responsibility Committee and Risk Management Committee.

Ms. Bali is a global business leader with extensive experience in leading large companies both in India and overseas. She served as Chief Executive Officer/ MD of Britannia Industries from 2005 to 2014. Prior to that, she worked with eminent multinationals like The Coca- Cola Company and Cadbury Schweppes Plc in a variety of marketing, general management and chief executive roles across the globe. Ms. Bali serves as an advisory board member of PwC India and is a non-executive director on the boards of Smith & Nephew Plc, Bunge Limited and CRISIL. At Syngene, Vinita Bali is a member of Nomination and Remuneration Committee, Corporate Social Responsibility Committee and Risk Management Committee.

Carl Decicco, Ph.D., has over two decades of experience in the pharmaceutical industry. He has delivered over 140 compounds into development with his teams, several of which have advanced into late-stage clinical testing. Carl retired as the Chief Scientific Officer at Foghorn Therapeutics in Cambridge, MA, in January 2022. Before Foghorn, he was the Head of Discovery at Bristol Myers Squibb (BMS). He is a Partner at Flagship Pioneering and serves on the Board of Cellarity Pharmaceuticals. Carl completed postdoctoral studies with Professor EJ Corey at Harvard University and was a teaching fellow at the University of British Columbia. He obtained his Ph.D. with Professor Gordon Lange in Organic Chemistry from the Guelph-Waterloo Center in Ontario, Canada. At Syngene, Carl is a member of the Risk Management Committee and the Science and Technology Committee.

Ms. Sharmila Abhay Karve is a Fellow member of the Institute of Chartered Accountants of India. She retired as audit partner from Price Waterhouse in June 2019. During her tenure in Price Waterhouse, she was an engagement partner with various large and prestigious Indian and multinational clients. She was the first female partner to be elected to the POC and to be appointed as the Chief Ethics Officer. In 2009 she was appointed as the Assurance Leader of the firm and was elevated to the role of Assurance Risk & Quality Leader in April 2012. In her assignment as Global Diversity Leader since December 2016, Ms Karve focused her efforts on bringing more diversity throughout the PwC network. At Syngene, Ms. Sharmila Abhay Karve is a member of the Audit Committee and Risk Management Committee and Chairman of the Stakeholders Relationship Committee.

Dr. Parmar holds a BA in molecular biology and medieval studies from Princeton University, a Ph.D. in experimental pathology from Harvard University, and an MD from Harvard Medical School. Currently, he is a Managing Partner at 5AM Ventures, a life sciences venture capital firm headquartered in San Francisco. Dr. Parmar serves on the Advisory Boards of Harvard Medical School, Penn Medicine, Princeton University’s Department of Molecular Biology, and the Grace Science Foundation. At Princeton University, Dr. Parmar worked on developmental genetics with Nobel Laureate Eric F. Wieschaus. A founding member of the COVID R&D alliance, Dr. Parmar also serves on the Boards of Akouos, Entrada, Homology, Rallybio and Vor Biopharma.